Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | TK1 | P04183 | 3/20 | 0.45 |
| ▸ | TK2 | O00142 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1411935 | 0.87 | TK1 (0.47) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL14855864 | 0.87 | TK1 (0.47) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL7607469 | 0.83 | TK1 (0.44) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL11206015 | 0.83 | TK1 (0.58) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL9443821 | 0.82 | RNASE1 (0.48) | LMNASMN1; SMN2TK1TK2CYP1A2 | |
| SCHEMBL21563855 | 0.82 | RNASE1 (0.48) | LMNASMN1; SMN2TK1TK2CYP1A2 | |
| SCHEMBL21563929 | 0.82 | TK1 (0.43) | LMNASMN1; SMN2TK1TK2 | |
| SCHEMBL537189 | 0.82 | RNASE1 (0.48) | LMNASMN1; SMN2TK1TK2CYP1A2 | |
| SCHEMBL6258929 | 0.81 | TK1 (0.50) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL7745421 | 0.81 | TK1 (0.50) | LMNASMN1; SMN2ALOX12ADRA1ATK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107511-A1 | OLIGONUCLEOTIDE END CAPS | BANK OF AMERICA, N.A. | 2017-04-20 | — | — | US | disclosed |
| US-9512164-B2 | Oligonucleotide end caps | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9453043-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | BANK OF AMERICA, N.A. | 2015-07-30 | — | — | US | disclosed |
| US-8975389-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| EP-2403863-B1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2013-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | LMNA 839/4885SMN1; SMN2 636/4885ALOX12 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.